Where ENZYME is life



INVESTOR PRESENTATION

NOVEMBER 2016



This presentation is for information purposes only and does not constitute, nor should be regarded as, an offer, invitation, inducement, solicitation or advertisement with respect to the purchase or sale of any security of Advanced Enzymes Technologies Limited ("AETL" or "Company") and no part of it shall form the basis of or be relied upon by you or any third party in connection with any investment decision, transaction, contract or commitment whatsoever. Further, it does not constitute a recommendation by AETL or any other party to sell or buy any securities of AETL. Any person who subsequently acquires the Company's equity shares must rely solely on the information contained in the prospectus (if resident in India) or the prospectus and international wrap (if resident outside India) to be issued in connection with the offer, issue and sale of the Company's equity shares, on the basis of which alone subscription for equity shares may be made.

All information contained in this presentation and any other information presented or discussed in connection herewith is provided solely by the Company and its Directors. The information contained in this presentation has not been independently verified by ICICI Securities Limited and Axis Capital Limited (the "Book Running Lead Managers"). No representation or warranty, express or implied is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of such information or opinions contained herein. The Book Running Lead Managers and their affiliates shall not have any liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of this presentation or its contents or otherwise arising in connection with this presentation.

The information in this presentation is provided as at the date of the draft red herring prospectus filed by the Company and is subject to change without notice, its accuracy is not guaranteed, it may be incomplete or condensed and it may not contain all material information concerning the Company. The Company, the Book Running Lead Managers and their respective affiliates do not have any obligation to, and do not intend to, update or otherwise revise any statements reflecting circumstances arising after the date of this presentation or to reflect the occurrence of underlying events, even if the underlying assumptions do not come to fruition, no representation or warranty (whether express or implied) is given in respect of any information in this presentation or that this presentation is suitable for the recipients' purposes. The delivery of this presentation does not imply that the information herein is correct as at any time subsequent to the date hereof and the Company has no obligation whatsoever to update any of the information or the conclusion contained herein to correct any inaccuracies which may become apparent subsequent to the date hereof. The Company assumes no direct or indirect responsibility for any errors or omissions in the contents of this presentation.

This presentation may not be used, reproduced, copied, distributed, published, shared, or disseminated in whole or in part, nor may its contents be disclosed by the recipient to any other person. Receipt of this presentation constitutes an express agreement to be bound by such confidentiality and the other terms set out herein. Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

AETL is proposing, subject to receipt of requisite approvals, market conditions and other considerations, to undertake an initial public offering of its equity shares (the "Offering") and has prepared and filed its draft red herring prospectus for the purpose of such Offering with the Securities and Exchange Board of India (the "SEBI"). The draft red herring prospectus is available on the website of SEBI at <u>www.sebi.gov.in</u> and the websites of the Book Running Lead Managers at <u>www.icicisecurities.com</u> and at <u>www.axiscapital.co.in</u>. You should note that investment in equity shares involves a high degree of risk and for details relating to the same, see the section titled "Risk Factors" of the aforementioned offer document.

This presentation is not for distribution in, nor does it constitute an offer of securities for sale, in the United States of America or any other jurisdiction where such distribution is unlawful and may not be forwarded to any U.S. person or to any U.S. address or any other jurisdictions where such distribution is not permitted. The Equity Shares of the Company are only being offered and sold outside the United States in reliance on Regulation S of the U.S. Securities Act of 1933, amended and the applicable laws of the jurisdiction where these offer and sales occur.



Table of Contents

Company Overview	4
Global Enzyme Market	12
Advanced Enzymes - A Unique Investment Case	15
Financial Overview	29



Company Overview



Global Enzyme Market



Company Overview

Advanced Enzymes is a research driven company with global leadership in the manufacturing of enzymes. We are committed to providing eco-safe solutions to a wide variety of industries like human health care and nutrition, animal nutrition, baking, fruit & vegetable processing, brewing & malting, grain processing, protein modification, dairy processing, speciality applications, textile processing and others. Our aim is to replace traditionally used chemicals with eco-friendly enzymatic solutions.



Mission

It is our mission to see that every human being is able to take advantage of the power of enzymes for well-being and leading a healthy life! Enzymes are specific and catalyse a wide variety of reactions and have been used widely as processing aids for improving the quality of the end products while reducing energy costs and reducing the overall carbon footprint of the process. It is our mission to see that every processing unit, that processes biological products, is able to take advantage of enzymes to derive a higher quality output, improve profitability and become more competitive.



Vision

Our vision at Advanced Enzymes is to become the largest, enzyme-based, value provider to consumers and processors globally!

Board of Directors





Mr. Kedar Desai Chairman and Independent Director

Mr. Kedar Jagdish Desai, is the Chairman of our Company and a Non-Executive and Independent Director on our Board. He holds a Bachelor's degree in Commerce and a Bachelor's degree in Law from the University of Mumbai. He is also a qualified solicitor from the Bombay Incorporated Law Society and has over 19 years of experience in the field of law.



Mr. Ramesh Mehta Independent Director

Mr. Ramesh Thakorlal Mehta is a Non-Executive and Independent Director of our Company since 1993. He passed the Intermediate Science Exam from University of Bombay. He has experience in the business of jewellery designing and manufacturing.



Mrs. Rupa Vora Independent Director

Mrs. Rupa Rajul Vora, is a Non-Executive and Independent Director of our Company since November 28, 2015. She is a Chartered Accountant by profession and has 31 years of experience. She was the Chief Financial Officer at Antwerp Diamond Bank N.V., after which she joined IDFC Group as a Group Director and Chief Financial Officer-Alternatives until June 2014. Currently, she serves as an independent director on a few corporate boards.



Mr. Vasant Rathi Non-Executive Director

Mr. Vasant Laxminarayan Rathi is the Promoter and a Non-Executive and Non-Independent Director of our Company. He holds a Bachelor's degree in Pharmacy from Nagpur University and degree of Master of Science from University of Hawaii. Has over 37 years of experience in the enzymes industry. He promoted & incorporated Cal-India in the year 1985 and has been associated with our Company since the year 1993. Mr. Rathi heads our international subsidiaries based in US.



Mr. C L Rathi Managing Director

Mr. Chandrakant Laxminarayan Rathi, is the Promoter and Managing Director of our Company. He holds a Bachelor's degree in Science (Chemical Engineering) from National Institute of Technology, Rourkela. Has over 37 years of experience in the enzymes industry. He is currently responsible for the management of the entire operations of the Company and its Indian subsidiaries, including strategic initiatives of our businesses.



Mrs. Savita Rathi Whole-time Director

Mrs. Savita Chandrakant Rathi, is the Whole-time Director of our Company. She has over 26 years of experience in the enzyme industry and has been associated with our Company since incorporation. She is responsible for the administration of the Company, management and supervision of Export-Import, Client relationship management and the Human Resource department of the Company.



Mr. Mukund M. Kabra Whole-time Director

Mr. Mukund Madhusudan Kabra, is the Whole-time Director of our Company. He holds a Bachelor's degree in Chemical Engineering from Sambalpur University. Has over 20 years of experience in enzyme industry and joined our Company in the year 1995. He is responsible for overlooking the manufacturing operations of the Company at Sinnar and Indore and for optimising the fermentation for existing products, strain improvement, downstream research and analytical research.







Piyush Rathi CBO A double graduate, Piyush first completed his Bachelors in Maths from Mumbai University and then in Finance from Michigan Tech University, USA. Subsequently he completed his MBA from SCMHRD and joined Advanced Enzymes in April 2005. In 2007 and in 2010, Piyush took charge of the Human Nutrition and Bio-Processing businesses respectively, and since 2014, he has also started developing the Animal Nutrition business internationally. Today, as Chief Business Officer, his key responsibility is to oversee the development of the company's business in Europe & Asia. He has also been instrumental in the recent acquisition of JC Biotech.



Beni Prasad Rauka CFO

Mr. Beni Prasad Rauka, a Chartered Accountant and Company Secretary by qualification, brings with him a rich experience of over 24 years in the Finance Industry. Mr. Rauka has worked with Category I Merchant Banking firms and finance companies in his long standing career. Mr Rauka joined Advanced Enzymes in the year 2000 as a consultant. Rauka has been leading the financial innovation in the new business structure and managing the financial activities of all group companies since 2007. As Group CFO, his prime objective today is to ensure that adequate and cost-effective finance is available for the group's strategic plans and investments.



Dr. Anil Gupta Vice President - Research & Development

Dr. Anil Gupta is a Ph.D. in Microbiology with over 18 years of experience in Industrial Biotechnology. Prior to his joining Advanced Enzymes, he also received the coveted Young Scientist Award Project from Department of Science & Technology, Govt. Of India and has worked as Principal Investigator in several research projects. Today, as Vice President - Research & Development, General Manager Research & Development, Dr. Gupta heads the process development, proteomics & the applied microbiology labs and leads the research effort in developing several new commercially-viable enzymes every year.




Dipak Roda VP - Market & Business Development

After having secured a Chemical Engineering degree from Bharati Vidyapeeth, Pune and a M.Sc Tech in Bioprocess Technology from UDCT, Mr. Dipak Roda began his career with Khandelwal Laboratories in their bio-technology division. Mr. Roda joined Advanced Enzymes in 2005 as a General Manager in Sales & Marketing. He played a key role in aligning the product baskets to the respective industries that they catered to. He led the company's entry into the large and competitive Chinese market through establishment of Advanced Enzyme Far East. Today, his focus is on growing the bio-processing business in the American continents and his key challenge is to build a strong marketing, sales & distribution network there.

Advanced Enzyme Technologies Limited – A Global Enzyme Player










- Supply enzyme products, enzyme blends & customised enzyme solutions
- Leverage R&D to deliver high quality products at globally competitive prices
- Assist customers worldwide to
 - ✓ Optimize their process
 - ✓ Improve their product quality
 - ✓ Save their time & money
 - ✓ Mitigate industrial impact on environment


Corporate Structure





(1)59.4% by AETL and remaining held by nominees of AET (2)84.86% by AETL and remaining held by nominees of AETL





Pharmaceuticals & Chemicals – ICICI **Business Banking & CNBC TV18**

Biotechnology -Govt. of Karnataka




Global Enzyme Market




Global Enzyme Market : Broad-based Growth led by Specialty Enzymes





World Enzyme Demand by Region

- Global growth to be led by Specialty Enzymes while Industrial Enzymes expected to see moderate growth
- North America dominates the global enzyme market
- Developing countries and especially Asia/Pacific and Central/South America to witness the fastest growth
- Indian enzyme market to grow from USD 105 mn in 2015 to USD 279 mn in 2022 at a CAGR of 15.0%



Source: Freedonia Report



Growing Population

Per capita Income, growing middle class and urbanization, particularly in rapidly developing economies

Global Industrial Enzymes

(USD Mn)	Biofuel	Cleaning Product	Food & Beverages	Animal Feed	Other Industrial
2012	515	920	1320	395	480
2022	640	1,690	2,555	745	670
CAGR	2.2%	6.3%	6.8%	6.6%	3.4%
	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark

Global Speciality Enzymes

(USD	Research &	Diagnostic	Other Specialty
Mn)	Biotechnology	Diagnostic	Biocatalysts Nutraceuticals
2012	815	430	255
2022	1,720	950	530
CAGR	7.8%	8.2%	7.6%
	-	-	\checkmark \checkmark

- Expansion of middle class population & meat consumption
- Adoption of Western-style diets
- Global focus on environment and reducing wastage

- Falling cost of DNA manipulation & sequencing
- Demographic shift to aid growth of diagnostic enzymes
- Perceived health benefits of nutraceutical enzymes

Source: Freedonia Report













Integrated Enzyme Company with presence across enzyme value chain Strong R&D, Enzyme Development & Manufacturing Capabilities



Diversified global operations with strong US focus Dedicated and Experienced Management Team



Strong Financial Performance & Stable Cash Flows







- Products catering to various user industries- presence in healthcare & nutrition and bio- processing verticals
- Diversified client base serving 700 customers worldwide

- Covering the entire gamut of activities R&D to commercial-scale manufacturing to marketing
- Presence Across The Enzyme Value Chain




Integration of operations helps provide customized value-added solutions



- Product development platform founded on extensive knowledge and expertise of enzymes and microorganisms
- Ability to develop unique enzymes & product solutions
- High capital with longer time required for R&D creates strong barrier for new entrants





customers spanning presence across 50 countries De-risked business model with top 10 customers having ~42% share of total revenues

Company Overview


æ





⊞





Company Overview

æ





R&D facilities with qualified and experienced team

- Focus on core competencies
- Focus on quality
- Intellectual property protection
- Depth of experience



Flexible and multipurpose manufacturing facilities

- High quality standards conforming to international accreditations
- Strict controlled processes
- Flexibility with batch size & customer requirements

Company Overview

Strong Research and Development Capabilities Enhancing Product Portfolio



50 Developed Indigenous Enzymes 55 Scientists, Microbiolog	D	ood Enzymes ossiers with EFSA ⁽¹⁾ egistered Patents	Significant R	2 &D Spend as % of Revenue ⁽²⁾ 5.80%
regulatory dossiersDevelop newer & improved microbial systems	 Improve recovery purification yields 		pport for onal applications	
 Purification & Characterisation of enzymes Generate data for filing 	 Upscaling fermentation Enhance efficiend downstream prod 	enzym various proces	p innovative e solutions for s food & non-food sing industries	 Custom application development Testing services for customers
Thane, Maharashtra Proteomics & Applied Microbiology	Sinnar, Maharashtra Process Develo & Optimizat	pment A	Thane, Aaharashtra pplication evelopment	Chino, California Laboratory Services




Flexible & Multipurpose facility with aggregate **Key Accreditations** fermentation capacity of 360 m³ Facility Capabilities Capacity Significance Country WHO GMP+ 22000 cGMP Fermentation, Nashik -1st fermentation 2005 ۲ **Recovery &** 120 m³ Unit I facility Formulations Nashik -Extraction & Oldest facility ۲ 36 mtpa Unit II Recovery Indian 9001: HALA **FDA** 2008 Fermentation. SEZ status. ۲ Indore **Recovery &** 240 m³ enjoys tax benefits Formulations Kosher GOTS NPOP Equipped Formulations with 5000 ۲ Thane (Animal 2,000 mtpa sq. ft. Nutrition) storage area Chino -Unit I **Blending**, Mixing Housed in US Practices strict controlled process 6,500 mtpa & Formulations Subsidiaries allowing for complete traceability of Chino -Unit II products

⊞

Diversified Global Operation & Customer Base





- Geographically diversified revenue base: 63.6% International Operations
- Diversified customer base: Top 10 accounting for 42% of revenue*
- 700 customers across 50 countries
- International operation continues to be an attractive growth lever

55+

- Sales & Marketing Team
- Domestic & International Markets

70

Distributor Network

India & Overseas



*For the year ended March 31, 2016

Company Overview



Well Positioned To Grow in the US Market through a well established base



U.S. Market Remains a Key Focus Area

- Strategically important business sizeable operations in U.S. through subsidiaries
- Supported by two manufacturing and two R&D facilities in U.S.

Product Focus

Nutraceuticals

Animal Nutrition & Food

And Focus Launched on Base USA Tausitions & Subsidiaries

Launched Own Branded Enzymes

- Marketed to Healthcare professionals & Consumers
- Multiple Channel Distribution:
 - Retail Stores,
 - E-Commerce,
 - Medical Professionals

Product Focus

Enzymes Based Nutraceuticals

Augmented Position Via Acquisitions & Subsidiaires



Advanced Enzymes, USA

Holding company for US operations



Cal India Foods International

Direct presence to market to small- tomiddle market companies in US



AST Enzymes


Consolidated presence in US


Strong Financial Performance














All figures in ₹ mn


All numbers are on Consolidated basis

ROE = Profit after tax / Average shareholder equity; RoCE = (Net Profit before Tax , Exceptional and extraordinary items + Finance cost) / Average (Net debt + Networth) EBIT and PAT Sept '15 numbers for calculating ROE and ROCE have been annualized

Strong Financial Performance




Net Working Capital (Days)
128




486 411 451 530 1,027 FY 12 FY 13 FY 14 FY 15 FY 16

Net Operating Cash Flow

Net Operating Cash Flow





All figures in ₹ mn


All numbers are on Consolidated basis

Net working capital days =((Trade receivables + inventories – Trade payables)/ Revenue from operations)*365 Net Debt = Long term debt + short term debt + current maturities of long term debt – Cash & Cash Equivalent



Key Strategies for Sustainable Future Growth





Broaden & Deepen Geographical Presence

- Deepen presence and increase market share in North America
- Position as an end-to-end enzyme & enzyme solution provider
- Enhance presence in branded enzyme supplements
- Increase distribution & reach
- Grow Europe & other Asian markets

- Nutrition
- Product & market penetration
- Build market share in food processing verticals
- Create more value for customers

Inorganic Expansion

- Acquisition of products/technology/ R&D to enhance capabilities, enter new market segments and expand presence
- Explore partnership / outlicensing / in- licensing to enter new geographies/ products
- Consolidate market share
- Financially viable acquisitions

Ð



Financial Overview





₹ in Million except per share data

Particulars	Q2FY17 Unaudited	Q1FY17 Unaudited	Q2FY16 Unaudited	H1FY17* Unaudited	H1FY16 Unaudited	FY16 Audited
Income from Operations	412.01	373.35	361.25	785.36	669.99	1,391.41
Expenses	296.52	320.17	321.22	616.67	564.96	1,102.08
Profit from Operations before Other Income, Finance Costs and Exceptional Item	115.49	53.18	40.03	168.69	105.03	289.33
Other Income	10.54	15.30	4.17	25.85	4.81	9.28
Profit from ordinary activities before Finance Costs and Exceptional Item (3+4)	126.03	68.48	44.20	194.54	109.84	298.61
Finance costs	4.48	11.68	18.14	16.17	27.12	43.71
Profit from ordinary activities before tax	121.55	56.80	26.06	178.37	82.72	254.90
Tax expense / (Credit)	28.05	19.72	5.28	47.76	17.23	45.95
Net Profit for the period	93.50	37.08	20.78	130.61	65.49	208.95
Earnings Per Share	4.26	1.70	0.95	5.95	3.01	9.60
* Statement of standalone unaudited financial results for the quarter and six months	ended 30 Septer	nber 2016				

⊜



₹ in Million

Particulars	H1FY17	FY16
EQUITY AND LIABILITIES		
Share capital	223.26	217.66
Reserves and surplus	2,120.03	1,524.35
Long-term borrowings	135.24	156.01
Other - Non-current liabilities	167.76	159.34
Short-term borrowings	70.45	294.52
Trade payables	111.05	89.87
Other current liabilities	208.60	164.04
TOTAL- EQUITY AND LIABILITIES	3036.39	2605.79
ASSETS		
Fixed assets	1064.06	1081.81
Long-term loans and advances	263.84	179.93
Other non-current assets	532.06	532.06
Inventories	447.79	474.02
Trade receivables	281.70	227.82
Cash and bank balances	18.08	15.36
Other current assets	429.16	94.80
TOTAL- ASSETS	3036.39	2605.79



₹ in Million except per share data

Particulars	Q2FY17 Unaudited	Q1FY17 Unaudited	Q2FY16 Unaudited	H1FY17* Unaudited	H1FY16 Unaudited	FY16 Audited
Income from Operations	908.03	944.98	704.68	1,853.01	1,388.59	2,937.62
Expenses	453.75	468.30	448.27	922.05	836.63	1,649.19
Profit from Operations before Other Income, Finance Costs and Exceptional Item	454.28	476.68	256.41	930.96	551.96	1,288.43
Other Income	5.95	4.16	3.41	10.12	4.06	12.89
Profit from ordinary activities before Finance Costs and Exceptional Item	460.23	480.84	259.82	941.08	556.02	1,301.32
Finance costs	9.31	17.86	27.12	27.17	46.97	78.56
Profit from ordinary activities before exceptional item and tax	450.92	462.98	232.70	913.91	509.05	1,222.76
Exceptional item	-	-	(40.14)	-	(40.14)	(40.96)
Profit from ordinary activities before tax	450.92	462.98	192.56	913.91	468.91	1,181.80
Тах	158.31	181.44	45.22	339.75	133.95	414.34
Net Profit for the period	292.61	281.54	147.34	574.16	334.96	767.46
Earnings Per Share	13.17	12.66	6.65	25.72	14.95	34.85

* Statement of consolidated unaudited financial results for the quarter and six months ended 30 September 2016

Balance Sheet (Consolidated) – Q2FY17



₹ in Million

Particulars	H1FY17	FY16
EQUITY AND LIABILITIES		
Share capital	223.26	217.66
Reserves and surplus	4,104.37	2,563.20
Minority interest	62.95	53.51
Long-term borrowings	138.44	387.52
Other - Non-current liabilities	186.07	175.63
Short-term borrowings	72.99	296.34
Trade payables	114.03	115.44
Other current liabilities	272.43	695.85
TOTAL- EQUITY AND LIABILITIES	5,174.55	4,505.15
ASSETS		
Fixed assets	3414.20	2923.59
Long-term loans and advances	184.34	180.44
Other non-current assets	4.33	3.92
Inventories	597.28	604.92
Trade receivables	467.91	417.97
Cash and bank balances	389.66	263.14
Other current assets	116.82	111.16
TOTAL- ASSETS	5,174.55	4,505.15

Consolidated Balance Sheet



All figures in ₹mn	As at March 31,						
	2012	2013	2014	2015	2016		
Equity and Liabilities							
Shareholder's Funds	960	1,619	1,664	2,101	2,787		
Minority interest	16	24	36	45	54		
Long-term borrowings	1,393	1,167	875	540	388		
Short-term borrowings	360	337	391	236	296		
Trade payables	182	169	104	116	123		
Other current liabilities	442	428	597	826	585		
Assets							
Tangible assets	496	1,157	1,149	1,111	1,144		
Capital work in progress	602	21	24	53	18		
Long-term loans and advances	120	139	168	160	180		
Inventories	291	446	499	526	605		
Trade receivables	327	391	324	372	418		
Cash and bank balances	53	37	26	43	263		
Short-term loans and advances	41	55	72	88	45		
Total	3,490	3,963	4,083	4,182	4,517		

⊜

Consolidated Profit & Loss Statement



All figures in Fruit	For the year ended March 31,						
All figures in ₹mn	2012	2013	2014	2015	2016		
Revenue from operations	1,717	2,204	2,395	2,231	2,938		
Other income	31	36	10	10	9		
Cost of materials consumed	478	511	471	477	590		
Gross Profit	1,239	1,693	1,924	1,754	2,347		
Gross Profit Margin (%)	72.2%	76.8%	80.3%	78.6%	79.9%		
Employee benefit expense	202	270	329	361	445		
Other expenses	414	528	557	483	520		
EBITDA	623	896	1,038	910	1,382		
EBITDA Margin (%)	36.3%	40.6%	43.3%	40.8%	47.1%		
Depreciation	55	75	99	90	87		
Finance Costs	122	96	132	93	79		
Tax expense	143	258	64	228	432		
Share of Minority interest	3	11	13	8	9		
Profit after tax	331	491	201	501	784		
PAT Margin (%)	18.9%	21.9%	8.4%	22.4%	26.6%		

Consolidated Cash Flow Statement




		For the year ended March 31,						
All figures in ₹mn	2012	2013	2014	2015	2016			
Profit before tax	477	760	278	738	1,225			
Adjustments for non-cash transactions	57	79	128	97	87			
Interest expenses	117	90	89	80	67			
Changes in working capital	(32)	(258)	155	(115)	(77)			
Income taxes paid	(125)	(254)	(194)	(264)	(270)			
Net Cash flows from operating activities (A)	486	411	451	530	1,027			
Net purchase of tangible assets	(344)	(151)	(95)	(92)	(133)			
Net purchase of intangible assets	(1,547)	(161)	(14)	(38)	(13)			
Net Cash flows from investing activities (B)	(1,887)	(308)	(105)	(109)	(139)			
Net borrowings	1,413	(210)	(86)	(262)	(514)			
Interest paid	(117)	(90)	(89)	(80)	(75)			
Net Cash flows from financing activities (C)	1,284	(32)	(215)	(359)	(616)			
Net (decrease) / increase in cash and cash equivalents (A + B + C)	(117)	71	131	62	272			


Shareholder Information



Stock Data (As on 11 November 2016)		1
Market Capitalization	42,755.4mn	
Shares Outstanding	22.3mn	F
Free Float (%)	6.5mn	F
Symbol (NSE/BSE)	ADVENZYMES /540025	[
Average Daily Volume	332189	E

Top Institutional Holders	
Institutions	OS (%)
Motilal Oswal Most Focused Multicap 35 Fund	1.43
Reliance Capital Trustee Co. Ltd-A/C Reliance small Cap Fund	1.35
DSP Blackrock Micro Cap Fund	1.28
Motilal Oswal Most Focused Midcap 30 Fund	1.11
Birla Sun Life Insurance Company Limited	1.11





Source: BSE, Bloomberg

Thank You





Advanced Enzymes

5th Floor, 'A' wing, Sun Magnetica LIC Service Road, Louiswadi Thane (W) 400 604, India Tel: +91-22-4170 3200 Fax: + 91-22-25835159